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Abstract
Background: Altered tumor suppressor p53 and/or CDKN2A as well as Ras genes are frequently found in primary and
metastatic melanomas. These alterations were found to be responsible for acquisition of invasive and metastatic potential
through their defective regulatory control of metalloproteinases and urokinase genes.
Methodology/Principal Findings: Using primary human melanoma M10 cells with altered p53, CDKN2A and N-Ras genes,
we found that inhibition of the proprotein convertases (PCs), enzymes involved in the proteolytic activation of various
cancer-related protein precursors resulted in significantly reduced invasiveness. Analysis of M10 cells and their gastric and
lymph node derived metastatic cells revealed the presence of all the PCs found in the secretory pathway. Expression of the
general PCs inhibitor a1-PDX in these cells in a stable manner (M10/PDX) had no effect on the mRNA expression levels of
these PCs. Whereas, in vitro digestion assays and cell transfection experiments, revealed that M10/PDX cells display reduced
PCs activity and are unable to process the PCs substrates proIGF-1R and proPDGF-A. These cells showed reduced migration
and invasion that paralleled decreased gelatinase MMP-2 activity and increased expression and secretion of tissue inhibitor
of metalloproteinase-1 (TIMP-1) and TIMP-2. Furthermore, these cells showed decreased levels of urokinase-type
plasminogen activator receptor (uPAR) and increased levels of plasminogen activator inhibitor-1 (PAI-1).
Conclusions: Taken together, these data suggest that inhibition of PCs activity results in decreased invasiveness of primary
human melanoma cells despite their altered p53, CDKN2A and N-Ras genes, suggesting that PCs may serve as novel
therapeutic targets in melanoma.
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Introduction
Frequently arising from precursor lesions know as atypical
nevi, melanomas constitute one of main causes of morbidity and
mortality, although when detected early, many melanomas are
curable by surgical intervention [1]. In addition to poor prognosis
due to their high tendency to form metastasis, advanced
melanomas are also highly resistant to various treatments,
including radiation and chemotherapy [2]. Recently, many
studies revealed that various genetic changes are usually
associated with the progression of the disease. These include
the loss or inactivation of tumor suppressor genes such as
CDKN2A and p53 [3,4] and alteration of other genes such as Ras
[5]. Indeed, the corresponding CDKN2A product (p16 protein)
was reported to act by blocking progression through the cell cycle
[3,4] and to suppress tumor invasion and metastasis by acting as
an inhibitor of expression of various matrix metalloproteinases in
tumor cells [6–8]. Similarly, p53 that encodes a multifunctional
transcription factor to mediate cellular responses to diverse
stimuli, including apoptosis, DNA repair, and cell cycle arrest
[9–11] was also found to regulate the proteolytic capacity of
various cells by directly controlling the expression of various
MMPs [12–14] and urokinase genes [15–17]. Indeed, the
promoter of several MMPs was found to contain a consensus
p53 binding element, which mediates activation of transcription
of these genes [12]. In addition wild-type and mutant p53
differentially regulate the activity of the promoters of MMPs,
suggesting a direct role for p53 inactivation in the extra cellular
matrix (ECM) degradation, leading to cancer cell invasion
[12,15,16,18]. In the same way, altered Ras gene was reported
to increase various MMPs and urokinase expression as well as
tumor cell invasion [19,20], whereas it’s suppression resulted in
reduced melanoma cell migration and invasion [21].
A wide range of proteins that control the metastatic character
of various tumor cells, including melanoma cells, such as
adhesion molecules, growth factors, growth factor receptors and
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that are converted to their bioactive forms directly or indirectly
by one or more of the 7 known subtilisin/kexin-like proprotein
convertase (PCs) family members. These include PC1, PC2,
Furin, PC4, PC5, PACE4, and PC7 [22–28]. Previously, altered
levels and activity of one or more of these PCs as well as their
substrates were reported to be associated with several human
cancers, suggesting a direct role of these proteases in the
acquisition of the tumorigenic and metastatic potential of tumor
cells [22–28]. In this study we found that inhibition of PCs in
primary human melanoma cells with altered tumor suppressor
genes CDKN2A and p53,a n dN-Ras gene suppress the invasive
phenotype by acting on the expression and/or activation of
several ECM-degrading enzymes and their inhibitors. These data
suggest that proprotein convertases may serve as novel thera-
peutic targets in the treatment of melanoma.
Materials and Methods
Cell culture and transfections
The primary melanoma M10 cells were derived from a 65-years
old female patient suffering from primary recurrent malignant
melanoma of the leg [29]. The MT10 and MG10 cells were
isolated from gastric and lymph node metastatic lesions that arose
from primary lesions 3 and 4 years later, respectively [30]. Cells
were maintained with RPMI 1640 media containing 10% FCS,
100 U/ml penicillin, and 100 mg/ml streptomycin (Invitrogen,
Cergy Pontoise, France). The M10 and Colo829 human
melanoma cells were stably transfected with empty pIRES2-EGFP
vector or with the same vector containing the full-length cDNA
encoding the general PCs inhibitor a1-PDX, as previously
described [25], using the Fugen 6.0 (Roche Diagnostics, Meylan,
France) according to manufacturer’s instructions. After cell
transfection, a mixture of G418-resistant (M10/PDX, Colo829/
PDX) cells were selected and screened for a1-PDX expression by
Western blotting. To generate single-mixture cells expressing the
a1-PDX inhibitor, the M10/PDX and Colo829/PDX cells were
cultured in the presence of 1 mg/ml Pseudomonas exotoxin A [25].
This toxin mediates cell death only after its cleavage by the PCs
[25,31]. In some experiments, cells were transiently transfected
with pIRES2-EGFP-V5 empty vector or containing the PCs
substrate PDGF-A cDNA [26]. Cells were grown in RPMI-1640
medium supplemented with 10% FCS, 100 U/ml penicillin,
100 mg/ml streptomycin, and 200 mg/ml Geneticin (G418).
RT-PCR
Following cellular RNA extraction using Trizol reagent (Life
Technologies, Inc.) according to the manufacturer’s instructions,
2 mg of total RNA were reverse transcribed using a reaction
mixture as previously described [25]. The reaction mixture was
incubated for 10 min at 25uC, then for 45 min at 42uC, and finally
for 5 min at 95uC. The upstream and downstream primers used in
this study were previously described [25,32,33]. The cDNA
amplification was performed using established procedures with
slight modifications [25]. Twenty-five cycles consisting of 15 s at
94uC, 15 s at 58uC, and 30 s at 72uC were used, and followed by a
10-min incubation at 72uC. The amplified DNA fragments were
analyzed without further purification by electrophoresis on a 1%
agarose gel.
Real-time PCR
One mg of total RNA was subjected to cDNA synthesis using the
Superscript II first strand cDNA synthesis system (Invitrogen, Cergy
Pontoise, France) and oligo dT18–20 as primers. The relative
quantification of specific mRNAs was performed by real-time PCR
using the StepOnePlus
TM Real-Time PCR System and PCR
Master Mix (Applied Biosystems, Courtaboeuf, France) according to
the manufacturer’s instructions. Briefly, the reaction mixture of the
reaction (20 ml) contained 2 ml of cDNA resulting of 5-fold dilution
of the RT mixture product, 2 x TaqMan Universal PCR Master
Mix, 0.3 mMo ft h ep r o b ea n d0 . 9mM of the forward and reverse
primers. PCR reaction was performed at 94uC for 15 s and at 60uC
for 1 min during 40 cycles. The transcription of b2-microglobulin
evaluated in each sample was used as endogenous control.
DNA sequencing
Double stranded polymerase chain reactions were carried out
on the relevant DNA, and the DNA products were purified by
ethanol precipitation and dissolved in 20 ml of sterile double
distilled water. Sequencing reactions were then carried out using
the Thermo Sequenase Dye Terminator Cycle sequencing premix
kit (Amersham,) using standard protocols for the ABI 373
sequencer. Data are presented in chromatogram form where
C=blue, A=green, T=red, and G=black.
Western blotting
Cells were lysed in phosphate-buffered saline (PBS) containing
2% Nonidet P-40 and protease inhibitors (Roche). Media or
lysates were subjected to SDS-polyacrylamide gel electrophoresis
in 8% gels and proteins were blotted onto nitrocellulose
membranes. The primary antibodies used were anti-IGF-I
Receptor (Santa Cruz Biotechnology) and anti-V5, for PDGF-A-
V5 detection (Invitrogen). Primary antibodies were revealed by
horseradish peroxidase-conjugated secondary antibodies (Amer-
sham, Pharmacia Biotech) and Enhanced Chemiluminescence
(ECL+Plus, Amersham Pharmacia Biotech) according to the
manufacturers’ instructions.
Measurement of TIMP-1, TIMP-2 and uPAR production by
tumor cells
Tumor cells were plated in 6-well plates and incubated at 37uC
in serum-free media. After 24 hours, media were collected and
analyzed for the presence of TIMP-1, TIMP-2 and uPAR using
ELISA kit according to the manufacturer’s instructions (R&D
Systems). Protein concentrations were calculated from a standard
curve.
Measurement of proprotein convertases activity
PCs activity in cells was assessed by evaluating their ability to
digest the universal PCs substrate, the fluorogenic peptide
pERTKR-MCA, as previously described [33]. In brief, tissue or
cell extracts were incubated with pERTKR-MCA (100 mM)
during the indicated time periods in the presence of 25 mM Tris,
(pH 7.4), 25 mM methyl-ethane-sulfonic acid, and 2.5 mM
CaCl2,a t3 7 uC and the fluorometric measurements were
performed using a spectrofluorometer (FLUOstar OPTIMA;
BMG Labtech, Cs/Marne, France).
Gelatin zymography
Zymography assay was done on serum-free conditioned media
derived from control cells or cells stably transfected with a1-PDX
[25,32]. SDS-PAGE gels were copolymerized with gelatin and
samples were loaded onto gels without boiling. The gels were
washed at room temperature in renaturing solution and in 10 mM
of Tris-HCl (pH 8). For the enzymatic reaction to take place, the
gels were incubated at 37uC in a solution of 50 mM of Tris-HCl
(pH 8) containing 10 mM of CaCl2. The gels were then stained in
Convertases and Melanoma
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indicative of gelatin lysis.
Cell migration and invasion assays
Cell migration and invasion were determined using 24-well
microchemotaxis chamber alone or precoated with 2 mg Matrigel
(Becton Dickinson Labware) [25,32]. Control M10 cells or M10
cells expressing a1-PDX cDNA were resuspended in serum-free
media and loaded into the upper chamber of each well. Cells were
incubated at 37uC for 24 h, after which, the filters were fixed and
stained with Diff-Quik (Medion Diagnostic). Cell migration and
invasion were quantified by the determination of the number of
cells that migrated directly through the membrane toward the
medium containing 10% serum that was used as a chemoattrac-
tant. Cells detected in each well were counted and the results were
represented as (number of migrated cells/number of total cells) x
100%. The human melanoma Colo829 control cells or stably
expressing a1-PDX cDNA (Colo829/PDX) were used for
comparison in these assays.
Results
Altered p53, CDKN2A and Ras genes in the human
primary melanoma cells M10
Previously, alterations in the tumor suppressor genes p53 and
CDKN2A were reported to be critical events in various cancers
including melanoma [4]. Similar mutations in various oncogenes
such as Ras were directly linked to melanoma [5]. Analysis of these
genes in the primary human melanoma M10 cells revealed that in
p53 gene, a CCT.TCT transition mutation were found leading to
a P98S substitution (Fig. 1A). Whereas analysis of CDKN2A gene in
these cells revealed its deletion and additional analysis of the
oncogenes CDK4, BRAF, K-Ras and N-Ras revealed that the latter
was altered. Indeed, two mutations were found that include an
insertion at the 27 bp and a substitution (CAA.CGA) leading to a
Q61R substitution (Fig. 1B). Analysis of the M10 cells-derived
metastatic MT10 and MG10 cells revealed the presence of
identical gene alterations (data not shown).
Expression of a1-PDX in human primary melanoma cells
To investigate the effect of PCs inhibition on the malignant
phenotypes of human primary melanoma cells, M10 cells were
stably transfected with pIRES2-EGFP empty vector or containing
the PCs inhibitor a1-PDX cDNA (M10/PDX). Using RT-PCR
analysis, we found that M10 cells express all the PCs found in the
secretory pathway namely Furin, PACE4, PC5 and PC7 (Fig. 2A).
Similarly, PCR analysis confirmed the presence of empty pIRES2-
EGFP vector and pIRES2-EGFP a1-PDX in the transfected cells
and that the M10 derived metastatic MT10 and MG10 cells also
expressed these PCs (data not shown). In M10/PDX cells, the
mRNA levels of the PCs analyzed were not affected significantly
following expression of a1-PDX (Fig. 2B).
PCs activity in M10/PDX cells
To evaluate the effect of a1-PDX on PCs activity in M10 cells,
we assessed their ability to convert two known PCs substrates into
mature form: PDGF-A tagged with the V5 epitope [26] and
insulin-like growth factor-I receptor (IGF-IR) [25]. As shown in
Fig. 2C, transfection of M10 cells with PDGF-A cDNA revealed
the ability of these cells to process pro-PDGF-A into mature
PDGF-A. In contrast, transfection of M10/PDX cells with PDGF-
A cDNA resulted in pro-PDGF-A processing blockade. Similarly,
analysis of proIGF-IR processing in these cells revealed that M10/
PDX cells failed to adequately process proIGF-IR (Fig. 2D). Using
an in vitro enzymatic digestion assay to assess the ability of tumor
cells to digest the universal PCs substrate, the fluorogenic peptide
pERTKR-MCA [33], we confirmed the presence of high PCs
activity in M10 cells that was inhibited following expression of PCs
inhibitor a1-PDX (Fig. 2E, 2F).
Figure 1. Chromatograms showing the altered genes detected in
human primary melanoma M10 cells. (A) Sequence analysis of p53,
CDKN2A and CDK4 genes in M10 cells revealed a P98S substitution in p53
gene and a CDKN2A gene deletion. The CCT.TCT transition in p53 gene is
indicated in Lane-1 and normal chromatogram picture for the relevant
section of p53 gene is shown for comparison in Lane-2. (B) Chromatograms
of the two NRas gene mutations found in M10 cells. Arrows indicate a
substitution (CAA.CGA) and an insertion at the 27 bp of the NRas gene. In
Lane-1, the CAA.CGA substitution in NRas gene is indicated, and normal
chromatogram for the relevant section of NRas gene is shown in Lane-2.
The sequence of the 27 bp insert in NRas gene is also shown. In these cells
no alterations were found in the BRaf and KRas genes.
doi:10.1371/journal.pone.0009992.g001
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analyzed in M10 cells using specific primers for the PCs found in the secretory pathway (Furin, PACE4, PC5, PC7) and reverse transcription-PCR
analysis assay. Note that all these PCs are expressed in the M10 cells. (B) Following total RNA extraction from indicated cells, real-time PCR analysis
was performed using specific primers for Furin, PACE4, PC5, PC7 as described in Materials and Methods. During PCR, the transcription of b2-
microglobulin that was evaluated in each sample was used as endogenous control. Results shown in the bar graph are expressed as ratio of PCs
mRNA transcripts (M10)/(M10/PDX) deduced from values derived from M10 and M10/PDX cells mRNA analysis. Data are shown as means 6 S.E of
three experiments performed in duplicate. Real-time PCR analysis revealed that expression of a1-PDX in M10 cells did not affect significantly the
expression levels of these PCs in M10 cells. Processing of proPDGF-A (C) and proIGF-IR (D) analyzed by Western blotting revealed that expression of
a1-PDX in M10 cells (M10/PDX) completely inhibited the processing of pro-IGF-1R and proPDGF-A. (E) PCs activity in M10 cells and M10/PDX cells was
assessed by evaluating the cell extracts for their ability to digest the universal PCs substrate, the fluorogenic peptide pERTKR-MCA at the indicated
time points. Expression of a1-PDX in M10 cells reduced their PCs activity. (F) Results shown in the bar graph represent the PCs activity at 2 hours of
incubation of the indicated tumor cells. Results are representative of three experiments and data are mean 6 S.E performed in triplicate.
***p,0.0001.
doi:10.1371/journal.pone.0009992.g002
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Boyden chamber assays were perfoemed using M10 and M10/PDX
cells (A, B) or Colo829 and Colo829/PDX cells (C)t oa n a l y z ec e l l
invasion in Matrigel. Data are shown as means 6 S.E of three
experiments performed in triplicates and indicate the percentage of
the migrating cells. Student’s t test was used for statistical analysis. ***,
P,0.001.
doi:10.1371/journal.pone.0009992.g004
Figure 3. Effect of PCs inhibition on tumor cell migration.
Boyden chamber assays were performd using M10 and M10/PDX cells
(A, B) or Colo829 and Colo829/PDX cells (C) to analyze cell migration.
Data are shown as means 6 S.E of three experiments performed in
triplicates and indicate the percentage of the migrating cells. Student’s t
test was used for statistical analysis. ***, P,0.001.
doi:10.1371/journal.pone.0009992.g003
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cells migration and invasion
To evaluate whether inhibition of PCs in primary melanoma
cells can affect their migration and invasion, cells were incubated
for 24 hours in a microchemotaxis chamber (Fig. 3A, 3B) or
chamber pre-coated with Matrigel (Fig. 4A, 4B). As illustrated, the
expression of a1-PDX in these cells decreased their ability to
migrate and invade. Similarly, stable expression of a1-PDX in
melanoma Colo829 cells (Colo829/PDX) resulted in reduced
migration (Fig. 3C) and invasion (Fig. 4C).
Effect of PCs inhibition on gelatinase enzymatic activity
and MMP-2/TIMP-1 and MMP-2/TIMP-2 balance
Following 24–48 hours of cell incubation under serum-free
conditions, media were collected and analyzed for their
enzymatic activity. As shown in Fig. 5A, media derived from
Figure 5. Effect of PCs inhibition on gelatinase activity and MMP-2/TIMP-1 and MMP-2/TIMP-2 ratios. (A) Serum-free media derived
from M10 and M10/PDX cells were collected and analyzed for gelatinase enzymatic activity as described in Materials and Methods. Following total
RNA extraction, real-time PCR analysis was performed using specific primers for MMP-2 (B), TIMP-1 (C), TIMP-2 (D)o rb2-microglobulin as described in
Materials and Methods. During PCR, the transcription of b2-microglobulin that was evaluated in each sample was used as endogenous control.
Results are expressed as mRNA transcript ratios. Data are shown as means 6 S.E of three experiments performed in duplicate. (E, F) The ratios of
MMP-2/TIMP-1 and MMP-2/TIMP-2 are deduced from data obtained in (B), (C) and (D). (G, H), Tumor cells were incubated at 37uC in serum-free
media. After 24 hours, media were collected and analyzed for the presence of TIMP-1 and TIMP-2 using ELISA kit. Results shown are representative of
3 experiments. Data are mean 6 SEM (n=6 per group). Student’s t test was used for statistical analysis ***, P,0.001.
doi:10.1371/journal.pone.0009992.g005
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Expression of a1-PDX in these cells resulted in decreased
MMP-2 activity. In contrast, the activity of MMP-9 did not
change significantly.
Previously, TIMP-1 and TIMP-2 were described as the major
naturally occurring inhibitors of MMP-2, although TIMP-2 was
reported to inhibit MMP-2 over 10-fold more effectively than
TIMP-1 [34]. To rationalize the observed reduced activity of
MMP-2 in M10/PDX cells, we analyzed the expression of MMP-
2 and their inhibitors TIMP-1 and TIMP-2 using real-time PCR
and ELISA assays. We found that the expression of MMP-2 in
these cells wasn’t affected by PCs inhibition (Fig. 5B), suggesting
that this reduced activity as revealed by the zymography assay is
mainly due to post-translational repression. Indeed, in M10/PDX
cells mRNA expression level of TIMP-1 and TIMP-2 was
significantly increased (Figs. 5C, 5D). Similarly, at the protein
level, the amount of TIMP-1 and TIMP-2 collected 24 hours
following incubation of cells in serum-free media was increased in
cells expressing a1-PDX, as determined by ELISA (Figs. 5G, 5H).
Evaluation of MMP-2/TIMP-1 (Fig. 5E) and MMP-2/TIMP-2
(Fig. 5F) ratios indicated that compared to control M10 cells, these
ratios were significantly decreased in M10/PDX cells.
Effect of PCs inhibition on uPA, uPAR and PAI-1
expression
Similarly, since the uPA/uPAR/PAI-1 system is also involved in
melanoma cell invasion [35], we analyzed the effect of PCs
inhibition on the expression levels of these molecules by real-time
PCR and ELISA assays in M10 and M10/PDX. Fig. 6 shows that
the level of uPA did not change significantly (Fig. 6A), PAI-1 was
increased (Fig. 6B), whereas the level of uPAR mRNA was
dramatically decreased (Fig. 6C). Similarly, at the protein level,
ELISA assay revealed that the amount of uPAR collected 24 hours
following incubation of cells in serum-free media was decreased
significantly in cells expressing a1-PDX (Fig. 6D).
Discussion
The loss of function of tumor repressor genes p53 and/or
CDKN2A contributes to the induction and/or over-expression of
Figure 6. Effect of PCs inhibition on uPA, uPAR and PAI-1 expression. (A–C), Following total RNA extraction from indicated cells, real-time
PCR analysis was performed using specific primers for indicated genes as described in Materials and Methods. Results are shown in the bar graph and
are expressed as the mRNA transcript ratios. Data are shown as means 6 S.E of three experiments performed in duplicate. Student’s t test was used
for statistical analysis. *, P,0.05 and ***, P,0.001. (D), Tumor cells were incubated at 37uC in serum-free media. After 24 hours, media were collected
and analyzed for the presence of uPAR using ELISA kit. Results shown are representative of 3 experiments. Data are mean 6 SEM (n=6 per group).
Student’s t test was used for statistical analysis ***, P,0.001
doi:10.1371/journal.pone.0009992.g006
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and urokinase, leading to increased tumor cells invasiveness [6,8–
12]. Accordingly, the restoration of p53 and/or CDKN2A
expressions was found to inhibit MMPs expression and tumor
cells invasion [6,8–12]. In this study, we found that inhibition of
activity of proprotein convertases (PCs) in human primary
melanoma cells with altered p53, CDKN2A and Ras genes, provides
a potent repression mechanism of primary melanoma cell
invasiveness by interfering with the expression and/or activity
of several extracellular matrix degrading enzymes and their
inhibitors.
It is well established that invasiveness and the ability of cancer
cells to migrate in vitro and in vivo is mediated by various
metalloproteases (including MMP-2 and MMP-9) and urokinase
plasminogen system (uPA, uPAR and PAI-1) [36]. Indeed, data
reported on the activity of MMPs in different cells and tissues,
indicate that various MMPs are capable of degrading most
components of the basement membrane and ECM, facilitating
tumor cell migration and invasion [35–37]. The proteolytic
activity of these MMPs is tightly regulated by their inhibitors
TIMPs. Thereby the equilibrium between activation and inhibi-
tion that affect the MMPs and their inhibitors leads to excessive
proteolysis or inhibition [35–37]. The regulation of invasion by the
convertases was previously reported in numerous studies. It was
demonstrated that convertases directly involved in the activation of
several MMPs ( MT-MMPs), or indirectly, as in the case of MMP-
2 [22]. Similarly, the binding of uPA to its receptor uPAR induces
its activation that in turn activates plasminogen and generates the
active plasmin involved in the degradation of ECM [37]. These
processes were previously reported to promote tumor invasion and
migration [37]. Thereby targeting these proteases and their
activators inhibits the migration and invasion of tumor cells. To
investigate whether inhibition of PCs in primary melanoma cells
represses the malignant phenotype of tumor cells with altered p53
and CDKN2A tumor repressor genes, we used primary human
melanoma M10 cells that we found to have deleted CDKN2A and
mutated p53 (Fig. 1). Analysis of corresponding gastric and lymph
node metastatic lesions, MT10 and MG10 cells, revealed the
presence of identical gene alterations. Following stable expression
of the general PCs inhibitor in M10 cells, activity of PCs was
repressed, as revealed by in vitro enzymatic digestion assay, as well
as by their inability to process PCs substrates pro-PDGF-A and
pro-IGF-1R (Fig. 2C, 2D). Indeed, these tumor cells expressed all
the PCs found in the secretory pathway namely, Furin, PACE4,
PC5 and PC7 (Fig. 2A, 2B). The inhibition of their PCs activity by
a1-PDX inhibited their migration and invasion (Fig. 3 and Fig. 4)
that was associated with reduced MMP-2 activity and increased
level of TIMP-1 and TIMP-2 (Fig. 5). These data are in agreement
with a previous report showing that over-expression of Furin in
tumor cells results in increased MMP-2 activity and cell invasion
[22]. In these studies, the increased MMP-2 activity in tumor cells
expressing Furin was linked to the increased activity of MT1-
MMP, which is processed by Furin [38]. In other systems,
expression of a1-PDX in tumor cells blocked the maturation of
MT1-MMP, leading to reduced MMP-2 activity and cell invasion
[22]. In the current study, we revealed that the PCs can also
control the activity of MMP-2 by acting on the expression levels of
MMP-2 inhibitors TIMP-1 and TIMP-2 (Fig. 5) and the levels of
uPAR and PAI-1 in tumor cells (Fig. 6). However, the inhibitory
effect of a1-PDX on MT1-MMP processing and MMP-2 activity
leading to reduced cell migration and invasion has not been ruled
out in our model. The critical role of the PCs in the proteolytic
maturation of multiple precursor substrates implicated in neoplasia
makes these enzymes attractive targets in cancer therapy [39].
Indeed, introducing mutations in several PCs substrates expressed
in various tumor cells resulted in reduced invasiveness and
tumorigenicity in nude mice [22-26,38]. Accordingly, over-
expression of Furin has been established in various types of
human cancers and has been linked to aggressive behavior of
tumor cells [22,23]. These changes were directly related to the
inhibition of Furin-mediated activation of several cancer-related
substrates [22,28]. Therefore, the observed reduced activity of
MMP-2 in M10/PDX cells suggests that inhibiting the PCs could
alter the invasive and metastatic phenotypes of melanoma cells
Figure 7. Schematic representation of the effects of PCs
inhibition on migration and invasion of human melanoma
cells with altered CDKN2A, p53 and Ras genes. The CDKN2A locus
codes for the tumor suppressors p16 and ARF that regulate cell cycle
progression, DNA repair and cell invasion via activating pRb, and the
p53 pathway via inhibiting the activity of MDM2, respectively.
Mutations or deletions of the CDKN2A gene result in altered MMPs/
TIMPs and/or uPA/uPAR/PAI-1 expression and activity, which in turn
lead to tumor cell invasion. The Ras gene is important for regulating the
ERK activity, and hence expression of MMPs and uPA/uPAR. An
activating mutation in the Ras gene can result in uncontrolled activity
of MMPs and the urokinase system, which can lead to increased
melanoma invasion. Blockade of PCs activity can reduce the expression
and/or generation of active MMPs, uPA and uPAR leading to reduced
tumor cells invasiveness. The asterisks indicate altered genes.
doi:10.1371/journal.pone.0009992.g007
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genes such as Ras (Fig. 7). It is likely that a1-PDX can block the
processing of other proteins implicated in the invasive potential of
tumor cells, such as growth factors and adhesion molecules, as
previously reported in vitro and in vivo models [22,23,25,38].
In conclusion, our results support the hypothesis that the
malignant phenotype of primary human melanoma with altered
tumor repressor genes p53 and CDKN2A can be abrogated by
inhibition of PCs activity (Fig. 7). These enzymes may thus
constitute novel therapeutic targets for melanoma treatment,
leading to the development and application of potent bio-available
PCs inhibitors.
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